Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche

HOFFMANN-LA ROCHE clinical programs — 286 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

HOFFMANN-LA ROCHE projects

286 ClinicalTrials.gov programs sponsored by HOFFMANN-LA ROCHE.

HOFFMANN-LA ROCHE has 286 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

286 programs

Clinical programs

Page 1 of 6

  1. 5-Fluorouracil

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  2. 5-Fluoruracil

    Hoffmann-La Roche

    Gastric Cancer

    phase 3 small molecule completed

    1 trial

  3. Afimkibart

    Hoffmann-La Roche

    Moderately to Severely Active Crohns Disease

    phase 3 small molecule active

    1 trial

  4. Aflibercept

    Hoffmann-La Roche

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  5. Alectinib

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. Aleglitazar

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 3 small molecule completed

    2 trials

  7. Atezolizumab

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  8. Atezolizumab

    Hoffmann-La Roche

    Urothelial Carcinoma

    phase 3 small molecule completed

    2 trials

  9. Atezolizumab

    Hoffmann-La Roche

    Melanoma

    phase 3 small molecule completed

    1 trial

  10. Atezolizumab

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 3 small molecule active

    1 trial

  11. BN42082

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  12. BN42083

    Hoffmann-La Roche

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  13. BN42358

    Hoffmann-La Roche

    Early Parkinson's disease

    phase 3 small molecule active

    1 trial

  14. BN42644

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    phase 3 other active

    1 trial

  15. BO25323

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  16. BO28984

    Hoffmann-La Roche

    Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  17. BO29554

    Hoffmann-La Roche

    Advanced or metastatic Non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  18. BO40336

    Hoffmann-La Roche

    Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  19. BO40729

    Hoffmann-La Roche

    Advanced Malignancies

    phase 3 small molecule active

    1 trial

  20. BO41423

    Hoffmann-La Roche

    Mild or moderate hemophilia A without FVIII inhibitors

    phase 3 small molecule active

    1 trial

  21. BO41843

    Hoffmann-La Roche

    ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

    phase 3 small molecule active

    1 trial

  22. BO42161

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  23. BO42162

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  24. BO42592

    Hoffmann-La Roche

    Non-squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  25. BO42777

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  26. BO42843

    Hoffmann-La Roche

    High-risk muscle-invasive bladder cancer

    phase 3 small molecule active

    1 trial

  27. BO42864

    Hoffmann-La Roche

    RET fusion−positive, metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  28. BO45217

    Hoffmann-La Roche

    KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 3 other active

    1 trial

  29. BX44273

    Hoffmann-La Roche

    This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally

    phase 3 small molecule active

    1 trial

  30. Baloxavir Marboxil

    Hoffmann-La Roche

    Influenza

    phase 3 small molecule completed

    1 trial

  31. Bendamustine

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    1 trial

  32. Bevacizumab

    Hoffmann-La Roche

    B-cell Lymphoma

    phase 3 small molecule terminated

    1 trial

  33. Bevacizumab

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  34. CA41705

    Hoffmann-La Roche

    Lupus Nephritis (LN)

    phase 3 small molecule active

    1 trial

  35. CA42750

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  36. CN42097

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  37. CO41685

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  38. CO44657

    Hoffmann-La Roche

    Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  39. CO45042

    Hoffmann-La Roche

    Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  40. CR44829

    Hoffmann-La Roche

    Choroidal neovascularization secondary to pathologic myopia

    phase 3 small molecule active

    1 trial

  41. Capecitabine

    Hoffmann-La Roche

    Gastric Cancer

    phase 3 small molecule terminated

    1 trial

  42. Carboplatin

    Hoffmann-La Roche

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  43. Crenezumab

    Hoffmann-La Roche

    Alzheimer's Disease

    phase 3 small molecule terminated

    1 trial

  44. Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  45. Crovalimab

    Hoffmann-La Roche

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  46. Crovalimab, Crovalimab

    Hoffmann-La Roche

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  47. Cytarabine

    Hoffmann-La Roche

    Leukemia, Myeloid, Acute

    phase 3 small molecule terminated

    1 trial

  48. Entecavir

    Hoffmann-La Roche

    Pediatric Immuno-Tolerant Chronic Hepatitis B

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does HOFFMANN-LA ROCHE have?

286 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.